A Long Term Follow-up Study of TScan TCR-T Products

Part of paid clinical trials in Duarte, California.

Sponsor
TScan Therapeutics, Inc.
Study ID
NCT06976736
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 110 Years
Healthy Volunteers
Not accepted

Interventions

  • Observational — OTHER
    Long Term Follow-Up for participants treated with TSC-100 or TSC-101 TCR-T products

Study Details

The purpose of this Long-Term Follow-Up (LTFU) study is to monitor participants who have previously received TSC-100 or TSC-101 TCR-T therapies in the TSCAN-001 study. Participants will be monitored for 15 years from the date of TCR-T cell therapy administration to assess long-term safety and efficacy.

Key Dates

Start date
Sep 9, 2025
Status verified
Sep 2025
Primary completion
Sep 30, 2040
Completion
Sep 30, 2040

Study Design

Enrollment
1,000 participants (estimated)

Arms

  • Arm: Observational
    No study drug will be administered during this trial. Participants previously treated with TSC-100 or TSC-101 in a TScan study will be evaluated for long-term safety and efficacy.

Primary Outcome Measure

Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) [ Time Frame: 15 years post TCR-T administration ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
City of HopeDuarteCalifornia91010
Monzr M Al Malki, MD
Monzr M Al Malki, MD (PRINCIPAL_INVESTIGATOR)
Mount SinaiNew YorkNew York10029-6696
Alla Keyzner, MD
Alla Keyzner, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Duarte, CA

By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
City of Hope· Duarte, CAMount Sinai· New York, NY

Related Studies